Lava Therapeutics NV 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
LAVA Therapeutics N.V. has been acquired by XOMA Royalty Corporation for $1.04 per share plus a contingent value right, with 91.1% of shares tendered.
LAVA Therapeutics N.V. announced the successful completion of XOMA Royalty Corporation's tender offer, leading to its delisting from Nasdaq and a change in company control.
LAVA Therapeutics N.V. shareholders overwhelmingly approved a proposed merger with LAVA Therapeutics New Topco B.V. and the appointment of new executive and non-executive directors at an Extraordinary General Meeting.
LAVA Therapeutics and XOMA Royalty amend their acquisition agreement, reducing the cash offer per share but lowering the minimum net cash condition and extending the tender offer.
XOMA Royalty Corporation has extended its tender offer to acquire all outstanding common shares of LAVA Therapeutics N.V. until October 17, 2025.
LAVA Therapeutics has postponed its Extraordinary General Meeting to early November 2025 to further discuss transaction terms with XOMA Royalty Corporation.
LAVA Therapeutics announced an agreement to be acquired by XOMA Royalty Corporation for $1.16-$1.24 per share plus a contingent value right, alongside discontinuing its LAVA-1266 program and reporting Q2 2025 financial results.
XOMA Royalty Corporation will acquire LAVA Therapeutics N.V. for a cash payment per share plus a contingent value right, following a unanimous board recommendation.
LAVA Therapeutics N.V. announced that its shareholders approved all seven proposals, including the adoption of 2024 financial accounts and reappointments of directors, at its Annual General Meeting held on June 11, 2025.
LAVA Therapeutics N.V. has announced the appointment of KPMG LLP as its new independent registered public accounting firm for the fiscal year 2025, replacing PricewaterhouseCoopers Accountants N.V., following the remediation of previously identified material weaknesses in internal controls.
LAVA Therapeutics announces Q4 and full year 2024 financial results, highlights progress in clinical trials, and initiates a strategic review accompanied by a restructuring plan including a 30% workforce reduction.
LAVA Therapeutics N.V. received a notification from Nasdaq on February 27, 2025, indicating non-compliance with the minimum bid price requirement, as its common shares traded below $1.00 for 30 consecutive business days.
LAVA Therapeutics is exploring strategic options to maximize shareholder value, including a potential sale or merger, while also implementing cost-cutting measures such as a workforce reduction of approximately 30%.
LAVA Therapeutics N.V. will begin filing as a U.S. domestic issuer effective January 1, 2025, requiring more detailed and prompt financial reporting.